Logo

American Heart Association

  28
  0


Final ID: MP635

Regional Differences in Outcomes in Adults after Percutaneous Coronary Intervention (PCI) for Stable Ischemic Heart Disease

Abstract Body (Do not enter title and authors here): Background:
Previous studies on Percutaneous Coronary Intervention (PCI) for Acute Coronary Syndrome (ACS) have found a disparate distribution of healthcare resources across U.S. regions, contributing to regional differences in cardiovascular outcomes. Whether regional variation in clinical outcomes exist among patients with Chronic Coronary Disease (CCD) who undergo PCI remains unknown.

Research question: Does regional variation affect clinical outcomes in patients with chronic coronary disease undergoing percutaneous coronary intervention in the United States?

Methods:
We included patients undergoing PCI for CCD between January 2016 and June 2022 using the Vizient® Clinical Database. We evaluated major adverse cardiovascular events (MACE) — encompassing in-hospital all-cause mortality, myocardial infarction (MI), or repeat coronary revascularization by PCI or CABG — across hospitals in the South, Northeast, Midwest, and West within one year of the index PCI. We also assessed secondary outcomes, including individual components of the composite, major bleeding, and cardiovascular-related hospitalizations. We adjusted for demographics, comorbidities, hospital characteristics, encounter information, and procedural information.

Results:
A total of 176,492 patients were included across 176 hospitals, with 22% of patients from hospitals in the South, 23.46% Northeast, 33.32% Midwest, and 16% from the West. When compared with hospitals in the South as the reference, all other regions had higher risk of MACE and repeat PCI (Figure 1). After adjusting for covariates, patients cared for in Midwest hospitals had a higher risk of MACE (relative risk [RR] 1.24, 95% Confidence Interval [CI] 1.19-1.30), all-cause in-hospital mortality (RR 1.25, 95% CI 1.09-1.43), MI (RR 1.37, 95% CI 1.24-1.51), major bleeding(RR 1.33, 95% CI 1.23-1.44), cardiovascular-related hospitalizations (RR 1.04, 95% CI 1.01-1.08), renal replacement therapy (RR 1.41, 95% CI 1.19-1.66), and repeat PCI (RR 1.21, 95% CI 1.15-1.27). In contrast, patients in the Northeast had the lowest relative risk of mortality (RR 0.69, 95% CI 0.57-0.84) and major bleeding (RR 0.72, 95% CI 0.64-0.81).

Conclusion:
Significant regional variation exists in clinical outcomes following PCI in patients with CCD. Understanding driving factors for these disparities represents a target for future quality improvement efforts.
  • Akman, Zafer  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Park, Dae Yong  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Rossi, Raiza  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Nouri, Armin  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Arya Nezhad, Shefa  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Al Mouslmani, Mohammad  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Chi, Kuan Yu  ( Jacobi Medical Center , Bronx , New York , United States )
  • Lapetina Arroyo, Roberto  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Nanna, Michael  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Author Disclosures:
    Zafer Akman: DO NOT have relevant financial relationships | Dae Yong Park: DO NOT have relevant financial relationships | Raiza Rossi: DO NOT have relevant financial relationships | Armin Nouri: DO NOT have relevant financial relationships | Shefa Arya Nezhad: DO NOT have relevant financial relationships | Mohammad AL Mouslmani: DO NOT have relevant financial relationships | Kuan Yu Chi: DO NOT have relevant financial relationships | Roberto Lapetina Arroyo: DO NOT have relevant financial relationships | Michael Nanna: DO have relevant financial relationships ; Consultant:HeartFlow, Inc.:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Cutting-Edge Insights in Cardiovascular Care: From Precision Therapies to System-Level Outcomes

Saturday, 11/08/2025 , 01:45PM - 03:00PM

Moderated Digital Poster Session

More abstracts on this topic:
An Unusual Presentation of Cerebellar Stroke Following the Removal of Microaxial Flow Pump

Liu Zi Qian, Alsheikh-kassim Mohammad, Karpenos Joseph, Frodey Kevin

A Systematic Review and Network Meta-Analysis of Metastatic Castrate-Resistant Prostate Cancer Therapy Cardiotoxicity Given Metastatic Hormone-Sensitive Prostate Cancer Treatment History

Aziz Moez, Swaby Justin, Deng Brett, Hartshorne Taylor, Desai Shubh, Zhang Allan, Xiao Daniel, Sanchez Darren, Imber Jared, Song Jeffrey, Rivas Alexis, Molony Donald, Guhan Maya, Ranganath Shreyas, Jacob Jerril, Ziaolhagh Ali, Ali Abdelrahman, Yusuf Syed, Canfield Steven, Iliescu Cezar, Monlezun Dominique, Higgason Noel, Brunckhorst Oliver, Roland Jerry, Owen Christopher, Iacobucci Alexander Samuel, Galan Jacob

More abstracts from these authors:
Duration of Potent P2Y12 Inhibitor-Based DAPT after Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Frequentist Pairwise and Network Meta-Analysis

Joseph Meghna, Goldsweig Andrew, Nanna Michael, Krishna Mrinal, Ezenna Chidubem, Akman Zafer, Rossi Raiza, Nouri Armin, Al Mouslmani Mohammad, Damluji Abdulla, Kutty Shelby

Real-World Data Show No Preventive Effect of SGLT2 Inhibitors on Cardiac Dysfunction from Cancer Therapy in T2DM Patients

Chi Kuan Yu, Nanna Michael, Nouri Armin, Lee Pei-lun, Jones Xaviar, Akman Zafer, Rossi Raiza, Arya Nezhad Shefa, Lapetina Arroyo Roberto, Gallegos Cesia

You have to be authorized to contact abstract author. Please, Login
Not Available